# the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy

> **NCT03230851** · PHASE4 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 210 (estimated)

## Conditions studied

- Coronary Atherosclerosis

## Interventions

- **DRUG:** aspirin 100mg/d therapy
- **DRUG:** aspirin 100mg/2d therapy
- **DRUG:** aspirin 100mg/3d therapy
- **DRUG:** aspirin 50mg bid therapy
- **DRUG:** aspirin 75mg/d therapy
- **DRUG:** aspirin 50mg/d therapy
- **DRUG:** indobufen 100mg bid therapy

## Key facts

- **NCT ID:** NCT03230851
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-20
- **Primary completion:** 2018-07-10
- **Final completion:** 2018-08-10
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2017-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03230851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03230851, "the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03230851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*